Lorazepam

Lorazepam · LORAZEPAM 2 mg/mL · Injection · Intramuscular; Intravenous · Fresenius Kabi USA, LLC

NDC 65219-0368-24 · 25 VIAL in 1 TRAY / 1 mL in 1 VIAL · ANDA · View full market →

The short version

4 companies supply this market — a reasonable cushion if one runs into trouble. It is in shortage right now — FDA lists the reason as “other”.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

1.1%chance of a new FDA shortage posting for lorazepam (injectable) in the next 90 days

sterile injectable · price up 94% YoY · OAI inspection at a producing facility (24 months)

For scale: the typical drug’s chance is about 0.1% — this one is 7× that.

Backtested statistical model over the whole market, not this package alone. Model details →

Where it's made

Fresenius Kabi USA, LLCUnited States
analysis · manufacture

Establishments this product's FDA label declares, located via FDA registration data. How we built this →

Is this a "specialty" drug?

There's no legal definition — it meets 1 of 6 public criteria. Why that matters →

Part D specialty tier
Costs ≥ $950/fill · avg $9.63 per prescription
Biologic (BLA)
Injectable / infused
Orphan-drug exclusivity
REMS program

Regulatory

Application: ANDA217598
TE code: AP
Approval date: Nov 18, 2024
Patents / exclusivity: None on file

Shortage history

In shortage now — Ativan, Injection, 2 mg/1 mL (NDC 0641-6000-10)Sep 5, 2018
Other
month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Ativan, Injection, 2 mg/1 mL (NDC 0641-6001-25)Sep 5, 2018
Demand increase for the drug
month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Ativan, Injection, 4 mg/1 mL (NDC 0641-6002-10)Sep 5, 2018
Other
month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Ativan, Injection, 4 mg/1 mL (NDC 0641-6003-25)Sep 5, 2018
Other
month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6044-25)Sep 5, 2018
Demand increase for the drug
month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Lorazepam, Injection, 2 mg/1 mL (NDC 0641-6046-10)Sep 5, 2018
Other
month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6045-25)Sep 5, 2018
Other
month 96 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Lorazepam, Injection, 2 mg/1 mL (NDC 65219-368-02)May 3, 2018
Demand increase for the drug
month 101 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Lorazepam, Injection, 2 mg/1 mL (NDC 76329-8261-1)May 3, 2018
month 101 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months
In shortage now — Lorazepam, Injection, 4 mg/1 mL (NDC 0641-6047-10)May 3, 2018
Other
month 101 — 5× the typical 20-month injectable shortage · model puts 25% odds it resolves within 6 months

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Lorazepam (Injection)

Labeler	Strength	First seen	Last seen
Hikma Pharmaceuticals USA Inc.	LORAZEPAM 2 mg/mL	Jul 15, 2026	Sep 3, 2026
Civica, Inc.	LORAZEPAM 2 mg/mL	Jul 15, 2026	Sep 2, 2026
International Medication Systems, Limited	LORAZEPAM 2 mg/mL	Jul 15, 2026	Sep 2, 2026
Fresenius Kabi USA, LLC	LORAZEPAM 2 mg/mL	Jul 15, 2026	Aug 31, 2026
Hikma Pharmaceuticals USA Inc.	LORAZEPAM 4 mg/mL	Jul 15, 2026	Aug 31, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Lorazepam — NDC 65219-0368-24," retrieved September 3, 2026, https://drugdashboards.com/drug/65219036824.

Free to cite with attribution — see how the data is put together.